Inebilizumab is a monoclonal antibody medication used to treat adult patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune disorder that affects the optic nerves and spinal cord. Inebilizumab is administered intravenously, usually once every six months. It is designed to bind to and block a human protein called CD19, which is involved in the body’s immune response. By blocking CD19, Inebilizumab is thought to reduce the immune system’s attack on the optic nerves and spinal cord, thus reducing the symptoms of NMOSD. It is the first treatment for NMOSD that has been approved by the U.S. Food and Drug Administration.
Inebilizumab, sold under the brand name Uplizna, is a medication specifically designed to treat adults suffering from Neuromyelitis Optica Spectrum Disorder (NMOSD). It falls under the category of humanized monoclonal antibodies, acting by binding to and eliminating CD19+ B cells, including plasmablasts and plasma cells.
Here's a more comprehensive explanation of Inebilizumab:
- Function: Inebilizumab works by targeting a protein known as CD19, specifically found on B-cells. B-cells are part of the immune system and are responsible for antibody production. In individuals with NMOSD, the immune system malfunctions and mistakenly attacks healthy cells within the central nervous system, leading to inflammation and potential disability. By eliminating these B-cells, Inebilizumab effectively reduces the production of harmful antibodies and lessens the immune system's attack on the nervous system.
- Medical Use: Inebilizumab is solely approved for treating adult patients diagnosed with NMOSD who are AQP4 antibody positive. AQP4 stands for aquaporin-4, a specific protein targeted by the faulty immune system in NMOSD.
- Administration: Inebilizumab is administered through intravenous infusion, a process where the medication is delivered directly into a vein.